On July 24, 2023 Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, reported that it has opened enrollment in the UK and Germany for its ASPIRE global clinical trial in the first-line treatment of metastatic pancreatic cancer (Press release, Panbela Therapeutics, JUL 24, 2023, View Source;utm_medium=rss&utm_campaign=panbela-opens-enrollment-in-uk-and-germany-for-aspire-trial-in-pancreatic-cancer [SID1234633390]). ASPIRE is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. Detailed information on the trial can be located at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We’re thrilled to bring on the UK and Germany for the ASPIRE trial and to now have the full complement of Countries open and actively enrolling," said Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela. "

Next up, we are focused on having all sites open for enrollment within the next couple months, and then towards the interim data analysis in early 2024." There are approximately 95 sites planned for throughout the United States, Europe, Australia, and South Korea, in the global Aspire trial. Panbela is committed to delivering a more effective treatment for pancreatic cancer, a deadly disease with few treatment options.